Immunovant, Inc.

IMVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001764013

Price chart

Open-market purchases and sales by IMVT insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 25, 20264:05 PM ETSep 23, 2026Van Tuyl ChristopherChief Legal OfficerSSaleCommon Stock−2.85K$36.36−$103.48K176.55K−1.6%SEC
Aug 28, 20264:27 PM ETAug 28, 2026Pande AtulDirectorSSaleCommon Stock−1.5K$43.27−$64.91K116.73K−1.3%SEC10b5-1
Aug 21, 20264:03 PM ETAug 20, 2026Gloria MelanieChief Operating OfficerSSaleCommon Stock−3.06K$44.16−$134.95K219.3K−1.4%SEC
Jul 24, 20265:59 PM ETJul 24, 2026Pande AtulDirectorSSaleCommon Stock−1.5K$39.80−$59.7K116.73K−1.3%SEC10b5-1
Jul 24, 20265:57 PM ETJul 23, 2026Girao TiagoChief Financial OfficerSSaleCommon Stock−6.8K$38.69−$263.01K240.8K−2.7%SEC

The largest institutional positions in IMVT at the end of Q2 2026.

Institutions holding IMVT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC16,186,469$623.66M0.03%−761,419−4.5%Reduced
Deep Track Capital, LP9,341,151$359.91M5.30%−2,185,820−19.0%Reduced
BlackRock, Inc.7,180,897$276.68M0.00%+606,400+9.2%Added
Farallon Capital Management, L.L.C.5,805,000$223.67M1.31%+4,259,000+275.5%Added
BAKER BROS. ADVISORS LP5,435,220$209.42M1.05%−22,661−0.4%Reduced